Enterohepatic circulation of methotrexate in rats in vivo.
The pharmacokinetics of the methotrexate enterohepatic cycle were studied in rats in vivo. For plasma levels of methotrexate between 10(-5) and 10(-8) M, biliary levels were directly proportional and concentrated 27-fold. When labeled methotrexate was administered in doses sufficient to achieve plasma levels of 10(-6) M, approximately 50% of methotrexate appeared in the bile in normal animals and up to 80% appeared in anephric animals. In spite of the high percentage of administered methotrexate which appeared in the bile, complete interruption of the enterohepatic cycle in otherwise normal animals did not affect the plasma decay curve of a bolus of methotrexate. The increased biliary excretion which occurred in animals with renal impairment was utilized with possible therapeutic implications. Bile drainage in these animals rapidly decreased plasma methotrexate levels compared to nondrained controls. This suggests that interruption of the methotrexate enterohepatic cycle may provide an alternative for the management of methotrexate toxicity associated with renal insufficiency.
D000818:Animals; D001646:Bile / Q000378:metabolism; D004764:Enterohepatic Circulation; D005260:Female; D007668:Kidney / Q000378:metabolism; D008657:Metabolic Clearance Rate; D008727:Methotrexate / Q000378:metabolism*; D051381:Rats; D011919:Rats, Inbred Strains
D008727:Methotrexate